Cosmos Pharmaceutical Revenue Rises 8.7% as Store Network Expands
COSMOS Pharmaceutical Corporation closed six stores under its scrap-and-build policy, ending the fiscal year with 1,708 locations in operation.
COSMOS Pharmaceutical Corporation (TSE-3349), a drugstore chain operator, reported consolidated revenue of 1,099,583 million yen for the fiscal year ended May 31, 2026, an increase of 8.7% from the prior year.
Net profit attributable to owners of the parent rose 3.4% to 32,046 million yen over the same period.
COSMOS Pharmaceutical's gross margin narrowed by 0.2 percentage points to 20.9%, as the company restrained price increases tied to inflation in order to protect its low-price positioning.
Selling, general and administrative expenses rose 8.4% to 187,330 million yen, reflecting inflation-driven cost increases and a larger store base.
COSMOS Pharmaceutical opened 105 new stores during the fiscal year across the Kanto, Chubu, Kansai, Chugoku, Shikoku and Kyushu regions.
The company closed six stores under its scrap-and-build policy and due to expiring leases, ending the fiscal year with 1,708 stores in operation.
COSMOS Pharmaceutical targets trade areas of roughly 10,000 residents per store, an approach it contrasted with competitors that pursue larger catchment areas to maximize scale.
Total assets grew 13.7% to 596,485 million yen at fiscal year-end.
Fixed liabilities rose 54.2% to 71,891 million yen at fiscal year-end.
The equity ratio fell by 1.5 percentage points to 47.6% at fiscal year-end.
Cash and cash equivalents fell 6.7% to 53,241 million yen at fiscal year-end.
COSMOS Pharmaceutical intends to fund future capital needs mainly through bank borrowings and leasing, drawing on the best available option in light of economic and financial conditions.